Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Cellmark to Buy DNA-Testing Shop Reliagene for $8.6M in Cash and Stock

NEW YORK (GenomeWeb News) — Orchid Cellmark said yesterday it plans to buy Reliagene Technologies, a forensic and paternity DNA-analysis company, for $5.6 million in cash and $3 million in Orchid Cellmark restricted common stock.
Reliagene, which earned $7.5 million in revenue in 2006, “fits the criteria we are seeking in accelerating the growth of our business through acquisitions,” Orchid CEO Thomas Bologna said in a statement.
He said there is “essentially no customer overlap” between the two companies, and “the combined forensic casework, CODIS, and paternity laboratory testing volumes should increase our operational efficiencies.”
Bologna added that Orchid expects the acquisition to begin to be accretive in the second half of 2008.
Financial details were not disclosed, but Orchid said the selling price may change based on Reliagene’s working capital, and part of its payment will be held in escrow until “certain conditions, including the seller’s indemnification obligations,” are met.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.